Navigation Links
Sangart Initiates Phase 2b Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
Date:6/14/2011

SAN DIEGO, June 14, 2011 /PRNewswire/ -- Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen and other gas delivery, today announced the initiation of a Phase 2b study designed to evaluate the efficacy and safety of MP4OX treatment plus standard of care in severely injured trauma patients with lactic acidosis due to hemorrhagic shock. MP4OX is a novel oxygen therapeutic agent that is designed to provide rapid oxygen delivery to ischemic tissues.

"Based on results from the preclinical and Phase 2a studies, MP4OX has shown its potential in improving outcomes in bleeding trauma patients," said Karim Brohi, Professor of Trauma Sciences at the Royal London Hospital. "These studies have shown that MP4OX may increase the delivery of oxygen to the body and prevent organs from failing when a patient is experiencing hemorrhagic shock.  This trial initiation is a key phase in finding a treatment that can improve patient outcomes after major trauma."

The clinical trial is a multi-center, randomized, double-blind, controlled study that will enroll approximately 360 patients who have suffered hemorrhagic shock with lactic acidosis across approximately 50 trial sites in 15 countries. The primary objective of the study is to measure the proportion of patients discharged alive from the hospital, as well as a number of secondary endpoints including lactic acidosis resolution. The dosing regimen in this study will include an initial dose of 250 mL of MP4OX plus up to three replacement doses of 250 mL each, all within 12 hours following the initial dose.

"The initiation of this study is another important step in bringing MP4OX to patients with medical conditions that deprive tissue of necessary oxygen," said Brian O'Callaghan, President and CEO of Sangart. "We remain committed to developing
'/>"/>

SOURCE Sangart, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sangart Announces Closing of $50 Million Series G Financing
2. Sangart, Inc. Receives U.S. Orphan Drug Designation for use of MP4CO in Patients with Sickle Cell Disease
3. Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
4. Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan
5. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
6. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
7. Masimo Initiates Limited Market Release of E1, Single-Patient-Use Ear Sensor for Pulse Oximetry Monitoring
8. Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients
9. American Regent Initiates Nationwide Voluntary Recall of Sterile Water for Injection, USP, 50 mL Single Dose Vial Due to Particulate Matter
10. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
11. BAETA Corp Initiates Clinical Trial at NYU School of Medicine to Measure Efficacy of Pain Recording Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , Aug. 4, 2015 HeartWare ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that its President and Chief Executive Officer, ... Canaccord Genuity 35th Annual Growth Conference at 8:30 a.m. ... being held August 12-13, 2015 at the InterContinental Boston. ...
(Date:8/4/2015)... 2015  The Pittsburgh Life Sciences Greenhouse (PLSG), the ... that one of its portfolio companies, Medrobotics Corporation, has ... Robotic System in the U.S.  ... Medrobotics," said John W. Manzetti , president and ... way since spinning out of The Robotics Institute at ...
(Date:8/4/2015)... Pharma Ltd. (the "Company") (NASDAQ: NTEC ), a ... on its proprietary Accordion Pill platform technology, today announced ... the United States of 5,025,000 of ... of $6.00 per ordinary share, before underwriting discounts and ... by the Company.  In addition, the Company has granted ...
Breaking Medicine Technology:HeartWare Presentation At The Canaccord Genuity 35th Annual Growth Conference To Be Webcast 2Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 2Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 3Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 2Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 3
(Date:8/4/2015)... , ... August 04, 2015 , ... Statement by Paul ... the introduction of the Mental Health Reform Act of 2015 by Senators ... mental health reform a reality in America. , “This legislation and H.R. ...
(Date:8/4/2015)... ... August 04, 2015 , ... assistPoint Partners, LLC is ... oncology patient assistance programs. Through a secure web portal, assistPoint connects Life Sciences, ... enterprise level, cloud-based application and workflow solution. This provides cancer center patient advocates, ...
(Date:8/4/2015)... ... August 04, 2015 , ... Healthy ... Origins® Cognizin® is a trademark for Citicoline, a nutrient that supports memory function ... those applications which have more of a semi-solid composition. Vegetarian capsules are ...
(Date:8/4/2015)... ... August 04, 2015 , ... It’s hard ... Medical & Day Spa in Santa Barbara, CA is offering the solution by ... that permanently eliminates sweat and odor glands in the underarms. This simple and ...
(Date:8/4/2015)... ... August 04, 2015 , ... Recent studies ... a rise in binge drinking among certain populations and specific locations. ... continuing to examine trends and evidence to help facilitate health care treatment to ...
Breaking Medicine News(10 mins):Health News:MHA Applauds Introduction of Mental Health Reform Act of 2015 2Health News:MHA Applauds Introduction of Mental Health Reform Act of 2015 3Health News:assistPoint.com Web Site Launched 2Health News:Healthy Origins® Introduces Cognizin® Citicoline in a Vegetarian Capsule 2Health News:Healthy Origins® Introduces Cognizin® Citicoline in a Vegetarian Capsule 3Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3Health News:DARA Responds To International Trends in Binge Drinking 2Health News:DARA Responds To International Trends in Binge Drinking 3
... University of the Rockies (UoR) has introduced a ... master,s or doctoral degree in Psychology."As the demand ... an increasing need for professionals to administer the ... provided," said Dr. Steve Kirkpatrick, Dean of the ...
... Letter to Governors Rendell, Douglas Says to Use Medicaid ... Feb. 23 In a new letter to National ... Douglas (R-VT), the Coalition to Protect Senior Care (CPSC), ... today urged the nation,s Governors to ensure new state ...
... 23 Nostrum Pharmaceuticals, LLC ("Nostrum"), a privately-held ... that it has obtained a worldwide license to ... derivatives and analogues ("Caerulomycin") for their novel indication ... Institute of Microbial Technology ("IMTECH"), Chandigarh, India, one ...
... teamed up with world famous "Hippocrates Health Institute" with ... of HHI are now able to take advantage of ... the source of what many doctors and alternative health ... health problems including obesity, skin problems, and even cancer, ...
... Star Sabrina Bryan Will Visit SchoolLEOTI, Kan., Feb. 23 ... the economy. One challenge was that the junior high gymnasium ... the students with no place to exercise indoors during the ... high managed to rally support for their dedication to health ...
... March 12, 2009 - 9:00 a.m. ET HOPKINTON, Mass., ... CALP ) will conduct a conference call discussing ... a.m. ET on Thursday, March 12. Kevin Hrusovsky, ... Financial Officer, will host the call. Management will discuss ...
Cached Medicine News:Health News:University of the Rockies Introduces Mental Health Administration Specialization for Psych Majors 2Health News:National Caregiver Coalition to National Governors Association: Establish State Task Forces to Monitor Medicaid Spending, Ascertain Funds Going to Protect Seniors 2Health News:National Caregiver Coalition to National Governors Association: Establish State Task Forces to Monitor Medicaid Spending, Ascertain Funds Going to Protect Seniors 3Health News:Nostrum Pharmaceuticals Obtains Worldwide Licensing Rights From IMTECH for Clinical Development of the Small Molecule Caerulomycin and Its Proprietary Derivatives for Their Novel Indication of Immunosuppression 2Health News:Nostrum Pharmaceuticals Obtains Worldwide Licensing Rights From IMTECH for Clinical Development of the Small Molecule Caerulomycin and Its Proprietary Derivatives for Their Novel Indication of Immunosuppression 3Health News:LuxSauna Teams With World Famous Detox Health Retreat 'Hippocrates Health Institute' 2Health News:Leoti, Kan. Junior High Finds Ways to Exercise, Wins National Health Contest 2Health News:Leoti, Kan. Junior High Finds Ways to Exercise, Wins National Health Contest 3Health News:Leoti, Kan. Junior High Finds Ways to Exercise, Wins National Health Contest 4Health News:Caliper Life Sciences' Fourth Quarter 2008 Financial Results Conference Call Notice 2
All BioWhittaker Cell Culture Reagent and Buffer products are manufactured in accordance with cGMP regulations and are cell culture tested to assure compatibility. , Typical Properties, Sterility : ...
...
... sulfate is effective against gram positive and ... by interfering with bacterial protein synthesis by ... Its suggested working concentration of 50 mg/L ... cells, thereby making a gentler alternative to ...
Gentamicin Reagent Solution (10 mg/ml) liquid...
Medicine Products: